Sivarajan, Rinu
Oberwinkler, Heike
Roll, Valeria
König, Eva-Maria
Steinke, Maria
Bodem, Jochen
Funding for this research was provided by:
Julius-Maximilians-Universität Würzburg
Article History
Received: 18 August 2021
Accepted: 29 June 2022
First Online: 8 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: The present study was funded by Evonik Operations GmbH/Medpalett AS which commercialises Healthberry 865® (BC/BL). JB and MS are named inventors on Evonik Operations' patent applications for (1) Preparations containing berry extracts for use in the prophylaxis and/or treatment of viral infections caused by Herpesviridae, (2) Combined preparation comprising an anthocyanin composition and an antiviral agent, (3) Preparations containing berry extracts for use in the prevention and/or treatment of viral infections caused by Paramyxoviridae, and (4) Treatment and prevention of infections by Herpesviridae with Delphinidin-3-glucoside treatment and prevention of infections by Herpesviridae with berry extracts. JB works as a consultant for Evonik Operations GmbH. All other authors (RS, HO, VR and EMK) have no competing interests.